Oxford BioMedica plc 20.7% potential upside indicated by JP Morgan

Oxford BioMedica plc with ticker (LON:OXB) now has a potential upside of 20.7% according to JP Morgan.



JP Morgan set a target price of 495 GBX for the company, which when compared to the Oxford BioMedica plc share price of 410 GBX at opening today (06/07/2023) indicates a potential upside of 20.7%. Trading has ranged between 277 (52 week low) and 575 (52 week high) with an average of 139,330 shares exchanging hands daily. The market capitalisation at the time of writing is £402,976,010.

Oxford Biomedica Plc is a United Kingdom-based viral vector specialist that is primarily focused on delivering therapies to patients. The Company and its subsidiaries are engaged in viral vector delivery systems, including those based on lentivirus, adeno-associated virus (AAV) and adenovirus. It provides solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. The Company has built a LentiVector platform, which is focused on a lentiviral vector delivery system. The Company is engaged in working on programs from the pre-clinical to commercial stages across a range of therapeutic areas with global partners. The Company has manufacturing, laboratory and office space across six facilities in Oxford, United Kingdom. The Company’s subsidiary, Oxford Biomedica Solutions LLC, has an AAV manufacturing facility near Boston, Massachusetts, the United States.